Department of Pathology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China.
Xinjiang Medical University, Urumqi, Xinjiang, China.
Anal Cell Pathol (Amst). 2022 Aug 31;2022:9303081. doi: 10.1155/2022/9303081. eCollection 2022.
GPNMB is a newly discovered tumour-promoting factor that may promote tumour cell progression by activating the PI3K/AKT pathway by EGFR. However, there are insufficient studies about GPNMB in ESCC. This study investigated the relationship between GPNMB and EGFR/PI3K pathway genes in ESCC.
The expression levels of GPNMB, EGFR, p-PI3K, and Ki-67 were examined using immunohistochemistry. Statistical analysis was done by SPSS 22.0 and R.
GPNMB mRNA expression is higher in ESCC compared with paracancerous tissues. The expression of EGFR, PIK3CA, PIK3CB, and AKT1 was increased in GPNMB upregulated samples. GPNMB expression was positively correlated with EGFR, p-PI3K, and Ki-67 expression. GPNMB was expressed higher in the AJCC III stage, lymph node metastasis, and moderately poorly differentiated patients. EGFR was higher expressed in patients with vascular invasion; p-PI3K expression in Kazak was higher than that in Han; Ki-67 expression was higher in tumour size ≥ 3 cm. Patients with high expression of GPNMB, p-PI3K, and Ki-67 had worse OS. p-PI3K, Ki-67, nerve invasion, and lymphatic metastasis were independent risk factors, and postoperative adjuvant therapy was a protective factor in ESCC.
As a tumour-promoting factor, GPNMB is expected to be a potential target for ESCC.
GPNMB 是一种新发现的肿瘤促进因子，它可能通过 EGFR 激活 PI3K/AKT 通路促进肿瘤细胞的进展。然而，目前关于 ESCC 中 GPNMB 的研究还不够充分。本研究探讨了 GPNMB 与 ESCC 中 EGFR/PI3K 通路基因的关系。
采用免疫组织化学法检测 GPNMB、EGFR、p-PI3K 和 Ki-67 的表达水平。采用 SPSS 22.0 和 R 进行统计学分析。
与癌旁组织相比，ESCC 中 GPNMB mRNA 的表达水平更高。在 GPNMB 上调的样本中，EGFR、PIK3CA、PIK3CB 和 AKT1 的表达增加。GPNMB 的表达与 EGFR、p-PI3K 和 Ki-67 的表达呈正相关。GPNMB 在 AJCC III 期、淋巴结转移和中低分化患者中的表达较高。EGFR 在有血管侵犯的患者中表达较高；哈萨克族患者中 p-PI3K 的表达高于汉族；肿瘤大小≥3cm 的患者中 Ki-67 的表达较高。GPNMB、p-PI3K 和 Ki-67 高表达的患者 OS 较差。p-PI3K、Ki-67、神经侵犯和淋巴转移是独立的危险因素，术后辅助治疗是 ESCC 的保护因素。
作为一种肿瘤促进因子，GPNMB 有望成为 ESCC 的潜在治疗靶点。
